Iambic Raises Over $100 Million in an Oversubscribed Round to Advance Its Portfolio of AI-Discovered Therapeutics and Leading Platform Technologies
Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced raising over $100 million in an oversubscribed financing round with balanced support from new and existing investors, including Abingworth, Alexandria Venture Investments, Alumni Ventures, ARK, Ascenta, Catalio, Everbright Biofund, Freeflow Ventures, Illumina Ventures, Mubadala, Pegasus Tech Ventures, Qatar Investment Authority, Regeneron Ventures, Sequoia, Tao Capital Partners, Terra Magnum Capital Partners, Wilson Sonsini Goodrich & Rosati, and others.
Iambic to Participate in November Investor Conferences
Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced its participation in the following November investor conferences:
Iambic Announces Enchant v2, its Next Generation AI Model for Predicting the Clinical Viability of Drug Discovery Programs
Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, published on major advances to Enchant, Iambic’s breakthrough multimodal transformer model for predicting clinical and preclinical endpoints related to the drug discovery and development process. This new version of Enchant marks a pivotal advance in the use of large-scale transformers for drug discovery and supports a fundamental hypothesis: with the right model, architecture, and training strategy, one can achieve exceptional predictive power even in the most data-constrained settings.
Iambic to Participate in Upcoming Investor Conferences
Iambic, a clinical-stage biotechnology company developing novel medicines using its AI-driven discovery and development platform, today announced its participation in the following investor conferences:
Iambic to Participate in Upcoming Investor Conferences
Iambic, a clinical-stage biotechnology company developing novel medicines using its AI-driven discovery and development platform, today announced its participation in the following investor conferences:
